<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Radioimmunotherapy is a new <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> treatment modality combining the effects of irradiation and monoclonal antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>90Y-ibritumomab tiuxetan is a monoclonal antibody directed against the CD20 antigen to which a radioactive isotope of <z:chebi fb="2" ids="33331">yttrium</z:chebi> is attached, used for treating follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (FL) </plain></SENT>
<SENT sid="2" pm="."><plain>Using this compound we treated 8 patients with FL relapsing or refractory to combinations of rituximab and chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> developed in 5, and severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and <z:hpo ids='HP_0001903'>anemia</z:hpo> in 3 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Serious <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> developed in 2 patients, one died </plain></SENT>
<SENT sid="5" pm="."><plain>Six patients responded to treatment, 4 are still in remission after a median follow-up of 15 months, 2 died of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Best response was achieved in low-risk patients with a low <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden </plain></SENT>
<SENT sid="7" pm="."><plain>90Y-ibritumomab tiuxetan is an effective treatment for FL with significant hematological toxicity and a high price </plain></SENT>
</text></document>